References
- Alam MI, Baboota S, Ahuja A, et al. (2011). Nanostructured Lipid Carrier Containing CNS Acting Drug: Formulation, Optimization and Evaluation. Cur Nanosci 7:1014–27
- Alam MI, Baboota S, Ahuja A, et al. (2012). Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res 46:1133–8
- Alam MI, Beg S, Samad A, et al. (2010). Strategy for effective brain drug delivery. Eur J Pharm Sci 40:385–403
- Al-Ghananeem AM, Malkawi AH, Crooks PA. (2011). Bioavailability of Δ9-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spraydelivery system in conscious rabbits. Drug Dev Ind Pharm 37:329–34
- Aungst BJ, Rogers NJ. (1988). Site dependence of absorption-promoting actions of laureth-9, Na salicylate, Na2EDTA, and aprotinin on rectal, nasal, and buccal insulin delivery. Pharm Res 5:305–8
- Bjerre C, Bjork E, Camber O. (1996). Bioavailability of the sedative propiomazine after nasal administration in rats. Int J Pharm 144:217–24
- Chen X, Lu Y, Du S, et al. (2010). In Situ and in vivo study of nasal absorption of Paeonol in rats. Int J Mol Sci 11:4882–90
- Chien YW. (1985). Transnasal systemic medications: fundamentals, developmental concepts, and biomedical assessments. Amsterdam, New York: Elsevier
- Chung FY, Donovan MD. (1996). Nasal pre-systemic metabolism of peptide drugs: substance P metabolism in the sheep nasal cavity. Int J Pharm 128:229–37
- Haque S, Shadab M, Alam MI, et al. (2011). Nanomedicines for Brain Targeting: a patent review. Recent Patent Nanomed 1:149–61
- Hirai S, Yashika T, Matsuzawa T, Mima H. (1981). Absorption of drugs from the nasal mucosa of rat. Int J Pharm 7:317–25
- Huang C, Kimura R, Nassar A, Hussain A. (1985). Mechanism of nasal drug absorption of drug II: absorption of .-Tyrosine and the effect of structural modification on its absorption. J Pharm Res 74:1298–301
- Hussain AA. (1998). Intranasal drug delivery. Adv Drug Deliv Rev 29:39–49
- Hussain MA, Aungst BJ. (1994). Nasal mucosal metabolism of an LH-RH fragment and inhibition with boroleucine. Int J Pharm 105:7–10
- Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 11:1–18
- Jabbal-Gill I. (2010). Nasal vaccine innovation. J Drug Targeting 18:771–86
- Kao HD, Traboulsi A, Itoh S, et al. (2000). Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm Res 17:978–84
- Maggio ET. (2011). Intranasal administration of active agents to the central nervous system. US Patent 20110129462A1
- Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 379:146–57
- Nagai T, Nishimoto Y, Nambu N, et al. (1984). Powder dosage form of insulin for nasal administration. J Control Rel 1:15–22
- Pires A, Fortuna A, Alves G, Falcao A. (2009). Intranasal Drug Delivery: How, Why and What for? J Pharm Pharm Sci 12:288–311
- Preda M, Leucuta SE. (2003). Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro.in vivo characterization. J Microencapsul 20:777–89
- Sakane T, Akizuki M, Yamashita S, et al. (1991). The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem Pharm Bull 39:2456–8
- Tas C, Ozkan CK, Savaser A, et al. (2006). Nasal absorption of metoclopramide from different Carbopol-981 based formulations: in vitro. ex vivo and in vivo evaluation. Eur J Pharm Biopharm 64:246–54
- Ugwoke MI, Kaufmann G, Verbeke N, Kinget R. (2000). Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm 202:125–31